secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001437749-23-013652
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q1 revenue up 4% to $37.7M; net loss widens, explores sale of freezer lines
--------------------------------------------------------------------------------

- Revenue $37.7M (+4% YoY); ex-COVID growth 16%; biopreservation media revenue +28%.
- GAAP net loss $13.7M (-$0.32/share) vs $7.4M loss in Q1 2022; adjusted EBITDA -$1.9M.
- Adjusted gross margin improved to 37% from 32% in Q4 2022; GAAP gross margin 35%.
- Exploring strategic alternatives for ULT cryogenic freezer businesses, including potential divestitures.
- Affirmed FY2023 revenue guidance $188-$202M (16-25% YoY growth); Q4'24 aspirational targets reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000143774923013652/0001437749-23-013652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000143774923013652/bioli20230510_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-013652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer